OpenResearchAlpha

JAMA Dermatology · 10 Nov 2026

Efficacy and Safety of Brepocitinib in Cutaneous Sarcoidosis

Misha Rosenbach, Bridget E. Shields, Margaret Coates, Ogugua Ndili Obi, Anne L. Marano, Aaron R. Mangold, Oluwakemi Onajin, Anna Haemel, David Fivenson, Daniel A. Culver, Marc A. Judson, Claire Hannah, Craig Smuda, Samantha Polly, Rashmi Unwala, Logan Harper, Manuel L. Ribeiro Neto, W. Ennis James, Paras Vakharia, Cuong V. Nguyen, Galen Foulke, Mina Al-Awqati, Matthew Helm, Sylvia Hsu, Rohit Gupta, Donna A. Culton, Robert Pariser, Jordan Talia, Matthew C. Baker, Katharina S. Shaw, Brendan Johnson, Matthew D. Cascino, Brian Mandell, Nadera Sweiss, Lauren Graham, Joseph Barney, Sotonye Imadojemu, Avrom S. Caplan, William Damskyh-index 16

0
Citations
no database records one yet
0
Citations in 2026
so far
16
Leading author's h-index
William Damsky, in QAI's scholar index
30
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • OpenCitations0
  • Crossref0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Importance Cutaneous sarcoidosis (CS) is a chronic granulomatous skin disease associated with substantial morbidity and no approved therapies. Objective To evaluate the efficacy and safety of brepocitinib, an oral, selective, tyrosine kinase 2 (TYK2) and Janus kinase 1 (JAK1) inhibitor, in adults with CS. Design, Setting, and Participants BEACON is an ongoing, global, multicenter, randomized, double-blind, placebo-controlled phase 2/3 trial. This prespecified interim analysis evaluated the 16-week, dose-ranging phase 2 portion of the study conducted between April 9, 2025, and July 18, 2025. Adults with biopsy-proven active CS were randomized 3:2:2 to receive brepocitinib, 45 mg; brepocitinib, 15 mg; or placebo once daily. Main Outcomes and Measures The primary efficacy outcome was change from baseline in the Cutaneous Sarcoidosis Activity and Morphology Instrument–Activity (CSAMI-A) score at week 16. Additional outcomes included achievement of Cutaneous Sarcoidosis Activity–Investigator Global Assessment (CSA-IGA) clear or almost clear with a 2 or greater category improvement, CSAMI-A response (≥50% relative improvement), 10-point or greater CSAMI-A score reduction, achievement of a CSAMI-A score less than 5, patient-reported outcomes, and safety. Results Thirty-one participants (mean [SD] age, 53.3 [9.6] years; 18 female individuals [58%] and 13 male individuals [42%]) were enrolled. Both brepocitinib doses achieved rapid, significant improvements in CS disease activity: by week 16, CSAMI-A scores improved by 22.3 points in the 45-mg group and 22.2 points in the 15-mg group compared with a 0.7-point improvement with placebo ( P < .001). Across increasingly stringent responder-based and cutaneous remission–oriented end points, efficacy consistently favored brepocitinib, 45 mg, supporting a dose-dependent treatment effect. Compared with placebo, brepocitinib, 45 mg, resulted in higher rates of CSA-IGA clear or almost clear disease (69.2% vs 0%; P = .01), CSAMI-A response (76.9% vs 0%; P = .003), ≥10-point CSAMI-A reduction (100% vs 14.3%; P < .001), and achievement of a CSAMI-A score of less than 5 (61.5% vs 0%; P = .005). Clinical benefit extended to difficult to treat phenotypes, including lupus pernio, despite protocol-mandated systemic glucocorticoid discontinuation, and was accompanied by substantial improvements in skin-related quality of life. No deaths or serious adverse events occurred. Conclusions and Relevance In the phase 2 portion of the BEACON randomized clinical trial, brepocitinib produced rapid, dose-dependent, and clinically meaningful improvements in CS. As the first randomized, placebo-controlled trial to demonstrate efficacy of a targeted therapy in CS, these findings support selective TYK2/JAK1 inhibition as a potentially promising therapeutic strategy for CS and support ongoing phase 3 evaluation. Trial Registration ClinicalTrials.gov Identifier: NCT06978725

What the data shows

  • No database records a citation yet, as is usual for a paper this new.
  • William Damsky has the highest h-index among the authors (16).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (39)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (30)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 10 more references

A free account opens the rest of the citing papers and references on every paper’s page.